MedDataX Logo

Study on Antigen-presenting Function of Gamma Delta T Cells in Sepsis and Its Molecular Mechanisms

NCT ID: NCT03379896

Last Updated: 2017-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-04

Study Completion Date

2020-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study on antigen-presenting function of gamma delta T cells in sepsis and its molecular mechanisms

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The latest definition of sepsis highlights the role of dysregulated host response to infection in organ dysfunction aggravation. Maintenance of immune homeostasis of septic patients through immunotherapy is the key breakthrough to improve success rate. Antigen-presenting cell (APC) is the bridge that connects the innate and adaptive immunity. Decrease of count and function of APC has been shown to be associated with worsened clinical outcomes in patients with sepsis. Gamma-delta T cells (γδ T cells) are the newly identified population of T lymphocytes. Recent studies have found that γδ T cells possess unique and powerful antigen-presenting function, making them the hot topic in infection and cancer research. Based on the results, the investigator plan to evaluate the antigen-presenting function changes of γδ T cells in septic status by analyzing the antigen-presenting related molecules on γδ T cells, antigen protein uptake ability, and their function on the proliferation and activation of CD8+ T lymphocytes. Furthermore, the investigator will explore the mechanism and signal pathways for the APC function changes of γδ T cells. Findings from this research could help explain the mechanism of sepsis induced immune dysfunction, enrich our understanding of the important role of γδ T cells, and build a good foundation for immunotherapy in sepsis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Antigen-presenting Function γδ T Cells

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sepsis

Patient diagnosed with sepsis according to the new sepsis definition (infection+SOFA≥2).

Collect peripheral blood sample

Intervention Type OTHER

Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.

Control

Age-matched healthy control

Collect peripheral blood sample

Intervention Type OTHER

Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collect peripheral blood sample

Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥18 year old;
2. a known or suspected infection based on clinical data at the time of admission and sepsis-induced dysfunction of at least one organ.

Exclusion Criteria

1. autoimmune disease,
2. history of transplantation,
3. acute tuberculosis,
4. chronic hepatitis B or C infection,
5. HIV infection,
6. active malignancy, and
7. long-term use of cortical steroids.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

West China Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kang Yan

Yan Kang, Director of Department of Critical Care Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xuelian Liao, MD

Role: CONTACT

Phone: 8613541023033

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

81701880

Identifier Type: -

Identifier Source: org_study_id